Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Consensus Recommendation of “Hold” by Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have been assigned an average rating of “Hold” from the twenty ratings firms that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $109.00.

A number of analysts have recently weighed in on ZBH shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. Redburn Partners set a $130.00 price target on Zimmer Biomet in a research report on Thursday, September 18th. Rothschild & Co Redburn started coverage on Zimmer Biomet in a report on Thursday, September 18th. They issued a “buy” rating and a $130.00 price objective for the company. JPMorgan Chase & Co. restated a “neutral” rating and issued a $100.00 target price (down previously from $115.00) on shares of Zimmer Biomet in a research note on Thursday, November 6th. Finally, Roth Capital reiterated a “buy” rating on shares of Zimmer Biomet in a research report on Thursday, August 7th.

Zimmer Biomet Stock Up 3.8%

Shares of ZBH stock opened at $97.09 on Wednesday. Zimmer Biomet has a fifty-two week low of $85.33 and a fifty-two week high of $114.44. The firm has a market capitalization of $19.24 billion, a PE ratio of 23.62, a P/E/G ratio of 2.29 and a beta of 0.67. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. The stock’s 50-day simple moving average is $96.98 and its 200-day simple moving average is $96.80.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. During the same quarter in the previous year, the company posted $1.74 earnings per share. The company’s revenue was up 9.6% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities analysts expect that Zimmer Biomet will post 8.22 earnings per share for the current year.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares in the company, valued at $711,656.95. The trade was a 18.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.39% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Zimmer Biomet by 0.9% during the 2nd quarter. Vanguard Group Inc. now owns 23,251,295 shares of the medical equipment provider’s stock valued at $2,120,751,000 after acquiring an additional 198,370 shares during the period. Dodge & Cox boosted its position in Zimmer Biomet by 5.1% during the third quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock worth $2,286,793,000 after purchasing an additional 1,118,710 shares in the last quarter. Capital International Investors grew its holdings in Zimmer Biomet by 11.5% in the third quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock valued at $743,749,000 after purchasing an additional 778,467 shares during the period. American Century Companies Inc. increased its position in shares of Zimmer Biomet by 8.7% in the second quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock valued at $520,752,000 after buying an additional 458,903 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Zimmer Biomet by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 5,124,776 shares of the medical equipment provider’s stock worth $465,480,000 after buying an additional 69,485 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.